SGX Stocks :: Your One Stop SGX Stocks Info Blog

• Revenue: +12% (2Q09), +12% (1H09)
• Net Profit: -76% (2Q09), -49% (1H09)
• Outlook: The Group remains cautious about its outlook for the rest of 2009 as the difficult operating climate lingers.
• Notwithstanding this, the Group is committed to overcoming current economic challenges by stepping up its long-term growth strategy implementation.
• Key to this effort is the ongoing investments in product R&D to maintain a strong innovative product pipeline.
• The Group will also continue to strengthen its business development efforts by further expanding domestic sales and capture opportunities to grow both internally and externally.
• The Chinese government's industry-stimulus package and ongoing health care reform extending health insurance coverage to the rural population will provide impetus for the growth of the Chinese pharmaceutical market.

FINANCIAL RECORDS

Revenue (RMB'000)

FY 1Q 2Q 3Q 4Q Total
2009 29,632 34,557
2008 26,310 30,784 31,096 30,089 118,279
2007 42,239 25,819 31,374 22,534 122,066
2006 30,474 48,992 33,869 21,092 134,427
2005 22,778 33,549 30,583 29,607 116,517
2004 NA NA NA NA 92,251
-----------------------------------------------------------
Earnings (RMB '000)

FY 1Q 2Q 3Q 4Q Total
2009 1,521 552
2008 1,716 2,346 9,220 (9,634) 3,648
2007 21,419 (2,564) 6,221 (3,495) 21,581
2006 10,517 28,701 15,210 (422) 54,006
2005 6,417 20,526 12,648 8,746 48,337
2004 NA NA NA NA 39,881
-----------------------------------------------------------
Dividends

FY Interim Final Special (SGD)
2009 NA
2008 NA NA NA
2007 NA NA NA
2006 NA 0.013 NA
-----------------------------------------------------------
Bonus / Rights / Stock Split

Date Type Details
NA
-----------------------------------------------------------
Share Data (RMB)

NAV = $1.296
EPS = $0.0089 (6M FY09)
No of Shares = 234,125,000
-----------------------------------------------------------

ANALYSTS' TARGET PRICES

Broker Recommendation Target Price Date
NA